FDA CBER Centralizes Biologics Safety Communications Archive Spanning 2017 to 2026

For biologics manufacturers navigating post-market surveillance obligations, FDA's Center for Biologics Evaluation and Research (CBER) maintains a centralized archive of safety and availability communications dating from 2017 through the current year, with pre-2017 records accessible via the FDA Archive. The resource carries direct relevance for QA directors and regulatory affairs leads responsible for tracking agency signals that may trigger CAPA reviews or labeling reassessments.

The archive is organized by calendar year, with communications from 2019 onward designated as archived and the 2020–2026 series presented as active reference material. Each annual index consolidates product-specific safety signals, shortage notifications, and discontinuation alerts issued by CBER across its regulated product categories, which include vaccines, blood and blood components, allergenics, tissues, and cellular and gene therapy products.

Adjacent resources linked from the same page extend the compliance utility of the archive. These include MedWatch adverse event reporting, Letters to Industry and Healthcare Providers, the Bovine Spongiform Encephalopathy (BSE) guidance repository, and the CBER Biologics Effectiveness and Safety (BEST) System. For manufacturers operating under 21 CFR Part 600 and ICH Q10 quality system frameworks, cross-referencing these channels against internal deviation logs and periodic product reviews represents a defensible surveillance practice ahead of CBER inspections.

Direct inquiries to CBER's Office of Communication, Outreach and Development can be directed to ocod@fda.hhs.gov or by phone at (800) 835-4709; the agency also issues real-time updates via @fdacber on Twitter/X. Regulatory leads monitoring shortage and discontinuation signals for supply continuity planning will find the CBER-Regulated Products: Shortages and Discontinuations index a parallel reference within the same portal.

Manufacturers conducting annual product reviews or preparing for pre-approval inspections should confirm that their surveillance procedures formally reference the CBER communications archive as a documented external data source.

Source: FDA CBER via What's New Vaccines Blood Biologics RSS Feed, 22 June 2026.